Report on the risk assessment of mephedrone in the framework of the Council decision on new psychoactive substances
In: EMCDDA risk assessments 9
7 Ergebnisse
Sortierung:
In: EMCDDA risk assessments 9
In: Sucht: Zeitschrift für Wissenschaft und Praxis, Band 56, Heft 3-4, S. 213-214
ISSN: 1664-2856
In: Sucht: Zeitschrift für Wissenschaft und Praxis, Band 51, Heft 1, S. 36-36
ISSN: 1664-2856
In: Substance use & misuse: an international interdisciplinary forum, Band 45, Heft 3, S. 330-340
ISSN: 1532-2491
In: European addiction research, Band 18, Heft 5, S. 228-245
ISSN: 1421-9891
<b><i>Background:</i></b> Although awareness of the misuse of medicines is increasing, data on the extent of the problem in the European Union (EU) are lacking. <b><i>Methods:</i></b> In order to assess the magnitude and severity of the problem, a systematic review of the literature on the misuse of analgesics, opioid substitution medicines and sedatives/hypnotics (with the exception of benzodiazepines) was conducted using the PubMed and Web of Science databases. Relevant literature was identified between 2001 and 2011. <b><i>Results:</i></b> The main groups of misused medicines include opioid analgesics, methadone, buprenorphine and Z-drugs. Regional trends in medicine misuse indicate heterogeneity across the EU with respect to misused medicine types and research activities. Prevalence, high-risk populations and factors contributing to medicine misuse are discussed. <b><i>Conclusion:</i></b> The implications of these findings for prevention, treatment, and policy in the EU are considered.
AIMS: To quantify changes in (i) potency (concentration of Δ(9)‐tetrahydrocannabinol; %THC), (ii) price (euros/g of cannabis) and (iii) value (mg THC/euro) of cannabis resin and herbal cannabis in Europe. DESIGN: Repeated cross‐sectional study. SETTING AND PARTICIPANTS: Data collected from 28 European Union (EU) member states, Norway and Turkey by the European Monitoring Centre for Drugs and Drug Addiction. MEASUREMENTS: Outcome variables were potency, price and value for cannabis resin and herbal cannabis in Europe, 2006–16. Inflation was estimated using the Harmonised Indices of Consumer Prices. Mixed‐effects linear regression models were used to estimate linear and quadratic time trends, with a random intercept and slope fitted to account for variation across countries. FINDINGS: Resin potency increased from a mean [95% confidence interval (CI)] of 8.14% THC (6.89, 9.49) in 2006 to 17.22 (15.23, 19.25) in 2016. Resin price increased from 8.21 euros/g (7.54, 8.97) to 12.27 (10.62, 14.16). Resin increased in value, from 11.00 mg THC per euro (8.60, 13.62) to 16.39 (13.68, 19.05). Quadratic time trends for resin potency and value indicated minimal change from 2006 to 2011, followed by marked increases from 2011 to 2016. Herbal cannabis potency increased from 5.00% THC (3.91, 6.23) to 10.22 (9.01, 11.47). Herbal price increased from 7.36 euros/g (6.22, 8.53) to 12.22 (10.59, 14.03). The value of herbal cannabis did not change from 12.65 mg of THC per euro (10.18, 15.34) to 12.72 (10.73, 14.73). All price trends persisted after adjusting for inflation. CONCLUSIONS: European cannabis resin and herbal cannabis increased in potency and price from 2006 to 2016. Cannabis resin (but not herbal cannabis) increased in the quantity of Δ(9)‐tetrahydrocannabinol per euro spent. Marked increases in resin potency and value from 2011 to 2016 are consistent with the emergence of new resin production techniques in European and neighbouring drug markets.
BASE